Director Sells GKOS 15,000 Shares for $1.9 Million

Glaukos director Marc Stapley exercised 15,000 stock options and immediately sold the underlying shares on Jan. 22, 2026 for about $1.92 million (weighted avg $127.71; sale price close $125.90), reducing his direct holdings from 52,449 to 37,449 shares (post-trade direct value ≈ $4.71M) and leaving no options outstanding; the trades were executed under a Rule 10b5-1 plan. The company, market cap ~$6.85B, reports TTM revenue of $469.82M and a TTM net loss of $87.61M, saw its stock fall ~25% in 2025 but rise ~4.3% in Jan 2026, and announced Jan. 28 FDA approval permitting re-administration of a supplement for glaucoma—an operational positive against a multi-year unprofitable backdrop.

Analysis

Market structure: The 15,000-share exercise-and-sale is large relative to the insider’s past median but tiny versus GKOS float (Stapley’s post-trade direct stake = 0.07% of shares), so market supply pressure is marginal. FDA re-administration approval is a near-term demand positive — expect modest revenue tailwind over 2–6 quarters if physician adoption accelerates — but persistent negative net income and a ~25% 1-year decline cap long-term multiple expansion. Cross-asset: equity volatility may tick up (options IV), while unsecured credit/bond spreads would only widen materially if cash runway or a financing signal emerges.

Risk assessment: Tail risks include adverse post-approval safety signals, Medicare/insurer reimbursement cuts, or an equity raise that dilutes ~10–30% within 6–12 months; any of these could drive >30% downside. Immediate (days) risk = news-driven repricing around FDA commentary; short-term (weeks–months) = adoption, procedure volumes, and quarterly results; long-term = profitability and potential M&A or restructuring. Hidden dependencies: adoption requires surgeon training and favorable reimbursement codes; second-order effect is platform stickiness if repeat dosing proves cost-effective.

Trade implications: Tactical long exposure sized 2–3% of portfolio on GKOS (ticker: GKOS) to capture FDA-driven re-rating, paired with a 1–1.5% short in medtech ETF IHI to hedge sector beta. Use options: sell 6–8 week covered calls (strike ~135–140) on new long position to monetize upside and buy a 3-month put spread (120/100) sized to cap downside to ~10–15% of position value. Avoid increasing credit exposure and set a hard stop-loss at -20% from entry or trim on any equity raise announcement.

Contrarian angles: The market may over-penalize this scheduled 10b5-1 sale — it’s liquidity-driven, not necessarily negative signal; upside is underappreciated if repeat dosing increases per-patient lifetime revenue by even low single-digit percentages, which historically has led medtech re-ratings of +20–40% over 6–12 months. Conversely, the consensus may underprice dilution risk: monitor cash, burn rate, and any SEC S-3/Filing within 30–90 days as a binary catalyst that should change position sizing quickly.

Key Decisions for Investors

• Establish a 2–3% long position in GKOS (buy shares around $120–130), target holding period 3–12 months to capture FDA adoption; set stop-loss at 20% below entry and trim to 50% if an equity raise is announced within 90 days.
• Hedge sector beta by shorting IHI equal to ~40–50% of the GKOS dollar exposure (i.e., 1–1.5% portfolio short) to isolate company-specific upside from medtech movements over next 3 months.
• Sell 6–8 week covered calls against new GKOS long position at strike $135–140 to generate yield and reduce cost basis; simultaneously buy a 3-month put spread 120/100 sized to cap maximum loss to ~10–15% of the long position.
• If company discloses cash runway <12 months or files a shelf/S-1 within 30–90 days, move to reduce equity exposure to <1% or switch to long-dated put protection (LEAPS) targeting strikes 80–100 for >12-month hedge.